Does TILDRAKIZUMAB-ASMN Cause Therapy cessation? 50 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 50 reports of Therapy cessation have been filed in association with TILDRAKIZUMAB-ASMN. This represents 3.1% of all adverse event reports for TILDRAKIZUMAB-ASMN.
50
Reports of Therapy cessation with TILDRAKIZUMAB-ASMN
3.1%
of all TILDRAKIZUMAB-ASMN reports
0
Deaths
3
Hospitalizations
How Dangerous Is Therapy cessation From TILDRAKIZUMAB-ASMN?
Of the 50 reports, 3 (6.0%) required hospitalization.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TILDRAKIZUMAB-ASMN. However, 50 reports have been filed with the FAERS database.
What Other Side Effects Does TILDRAKIZUMAB-ASMN Cause?
Product dose omission issue (363)
Drug ineffective (223)
Psoriasis (86)
Death (84)
Product storage error (74)
Self-medication (74)
Off label use (66)
Condition aggravated (63)
Rash (54)
Pruritus (52)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which TILDRAKIZUMAB-ASMN Alternatives Have Lower Therapy cessation Risk?
TILDRAKIZUMAB-ASMN vs TILIDINE
TILDRAKIZUMAB-ASMN vs TIMOLOL
TILDRAKIZUMAB-ASMN vs TIMOLOL\TRAVOPROST
TILDRAKIZUMAB-ASMN vs TINIDAZOLE
TILDRAKIZUMAB-ASMN vs TINZAPARIN